Key Highlights
- 2.4% is the gap between Amgen (NASDAQ:AMGN) at USD 436.09 and its 52-week high of USD 447.03, per published market data on October 16, 2026 intraday. The 52-week low is USD 288.00, so the shares sit 51.4% above it (own arithmetic).
- USD 10.054 billion was second quarter revenue at Amgen (NASDAQ:AMGN), up 9.5% from USD 9.179 billion (own arithmetic), with non-GAAP EPS of USD 6.29 against USD 6.02 a year earlier, per the company release for the quarter ended June 30, 2026.
- USD 22.30 to USD 23.50 is 2026 non-GAAP EPS guidance, on revenue of USD 38.2 billion to USD 39.4 billion. At the USD 22.90 midpoint, Amgen (NASDAQ:AMGN) trades at 19.0 times forward EPS (own arithmetic).
- USD 387.93 is the average analyst target in published market data, 11.0% below the USD 436.09 price (own arithmetic). Of 30 analysts, the consensus rating is Hold, with targets from USD 200 to USD 500 for Amgen (NASDAQ:AMGN).
Price Action and Valuation Context
Amgen (NASDAQ:AMGN) rose 0.47% to USD 436.09 on October 16, 2026 per published market data, with an RSI of 64.9 and relative volume of 0.1x early in the session. The 50-day range was USD 375.65 to USD 444.12. The dividend is USD 2.52 a quarter, up 6%, or USD 10.08 a year, a 2.3% yield (own arithmetic). The third quarter report date was not confirmed in the material reviewed; the second quarter was reported August 4, 2026.
Earnings Drivers and Margins
Second quarter volume growth drove product sales of USD 9.537 billion, up 9%. Repatha sold USD 953 million, up 37%, Evenity USD 714 million, up 38%, Tezspire USD 486 million, up 42%, and Uplizna USD 335 million, up 90%. The biosimilar Pavblu rose 121% to USD 287 million. Non-GAAP operating margin was 48.4%, down 0.5 percentage points, and free cash flow was USD 3.489 billion against USD 1.911 billion. Published market data shows EPS beat a USD 5.62 consensus and revenue a USD 9.43 billion consensus.
MariTide, Analyst Views and Risks
Several Phase 3 MariTide studies are ongoing, including MARITIME-1 and MARITIME-2, and three diabetes studies are scheduled to start in 2026. The drug begins monthly and aims to maintain with as few as 4 or 6 doses per year. As of August 11, 2026, Oppenheimer had a USD 450 target and TD Cowen USD 452, while Bank of America held USD 317 with an Underperform rating. Debt was USD 57.3 billion against USD 14.0 billion of cash at June 30, 2026, a net USD 43.3 billion (own arithmetic), and no shares were repurchased.
Where Things Stand
It depends. Amgen (NASDAQ:AMGN) can break its USD 447.03 high if the next quarter confirms volume-led growth in Repatha, Evenity and Tezspire, because earnings beat consensus and 2026 guidance sits at USD 22.30 to USD 23.50. The case against is that the average target of USD 387.93 is 11.0% below the price, the consensus is Hold, and MariTide has no Phase 3 efficacy data to price in. Net debt of USD 43.3 billion limits flexibility. The report date was not confirmed in the material reviewed.






Please wait processing your request...